Market Overview

UPDATE: Citigroup Reduces PT to $77 on Becton, Dickinson and Company on Headwinds to Outlook

Related BDX
Medical Device ETF in Focus on Recent Merger Activity - ETF News And Commentary
Stifel: CareFusion Corporation Deal May Have Far-Flung Effects

Citigroup reiterated its Neutral rating on Becton, Dickinson and Company (NYSE: BDX) and reduced its price target from $78 to $77.

Citigroup noted, "The macro environment continues to remain volatile with end markets and Europe little improved, healthcare utilization and pricing remaining headwinds, and headline slowing emerging market growth a near-term overhang. However, new product roll-outs with the BD Insyte Autoguard, BD Nexiva with diffusion tip, and BD Mosaic hMSC Cell Culture Medium should provide some growth opportunities, while operating improvements with ReLoCo and ReKindle add leverage to the bottom line. F2H12 margins are expected to improve over F1H12, so F3Q results should begin to show some expansion."

Becton, Dickinson and Company closed at $74.79 on Friday.

Latest Ratings for BDX

DateFirmActionFromTo
Oct 2014Bank of AmericaMaintainsNeutral
Oct 2014Canaccord GenuityMaintainsHold
Oct 2014Argus ResearchMaintainsBuy

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters